Abstract
The fixed-combination of Cal/BD aerosol foam is now entering the Italian market. This drug was developed with a technology that allows an enhanced penetration of the active ingredients into the skin. This enhanced penetration improves local bioavailability and, consequently, Cal/BD aerosol foam therapy is associated with improved clinical outcomes if compared with other products with the same components. The efficacy and safety of Cal/BD aerosol foam were confirmed both in clinical trials and in "field-practice" studies. This short review discusses current evidence on the Cal/BD aerosol foam combination; some preliminary data collected in the Italian clinical practice will be also presented.
MeSH terms
-
Administration, Cutaneous
-
Aerosols
-
Betamethasone / administration & dosage
-
Betamethasone / adverse effects
-
Betamethasone / analogs & derivatives*
-
Betamethasone / pharmacokinetics
-
Biological Availability
-
Calcitriol / administration & dosage
-
Calcitriol / adverse effects
-
Calcitriol / analogs & derivatives*
-
Calcitriol / pharmacokinetics
-
Dermatologic Agents / administration & dosage*
-
Dermatologic Agents / adverse effects
-
Dermatologic Agents / pharmacokinetics
-
Drug Combinations
-
Humans
-
Italy
-
Psoriasis / drug therapy*
-
Psoriasis / pathology
-
Skin Absorption
-
Treatment Outcome
Substances
-
Aerosols
-
Dermatologic Agents
-
Drug Combinations
-
betamethasone dipropionate, calcipotriol drug combination
-
Betamethasone
-
Calcitriol